Teladoc Health, Inc. (TDOC) Stock Price & Analysis

Teladoc Health, Inc. (TDOC) rose 1.27% to USD 8.77 as of July 25, 2026 at 01:44 UTC, according to Nexqual real-time market data.

TDOC last closed at USD 8.66; the session ranged USD 8.71–9 on volume of 4,345,443 shares. Market capitalization is $1.58B, with a 52-week range of USD 4.4–9.89 (NYQ). Source: Nexqual, July 25, 2026 at 01:44 UTC.

Key Statistics (as of July 25, 2026 at 01:44 UTC)

PriceUSD 8.77
Change▲ 1.27% (up)
Previous CloseUSD 8.66
OpenUSD 8.81
Day RangeUSD 8.71 – 9
52-Week RangeUSD 4.4 – 9.89
Volume4,345,443 shares
Market Cap$1.58B
ExchangeNYQ

Technical Analysis (TDOC)

Nexqual's technical model rates TDOC "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:44 UTC.

Overall SignalBUY
RSI (14)50.83 (neutral)
vs SMA50Above (USD 7.97)
MACD0.33 (positive)

Analyst Ratings (TDOC)

Wall Street analysts rate TDOC "Hold" based on 19 analysts, with a mean price target of USD 7.97 (range USD 5–11), per Nexqual as of July 25, 2026 at 01:44 UTC.

Consensus RatingHold
Analyst Count19
Mean TargetUSD 7.97
High TargetUSD 11
Low TargetUSD 5
Buy / Hold / Sell6 / 18 / 0

Earnings (TDOC)

Next Earnings Date2026-07-29
EPS EstimateUSD -0.23
Revenue Estimate$616.33M

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD -0.28 vs est -0.39 ▲ beat
2025-12-31USD -0.1 vs est -0.22 ▲ beat
2025-09-30USD -0.19 vs est -0.31 ▲ beat
2025-06-30USD -0.15 vs est -0.31 ▲ beat

Source: Nexqual, July 25, 2026 at 01:44 UTC.

Financials & Fundamentals (TDOC)

Total Revenue$2.51B
Revenue Growth (YoY)-2.50%
Gross Margin+69.29%
Operating Margin-7.94%
Profit Margin-6.81%
ROE-12.39%
Debt / Equity77.68
Current Ratio2.8
Total Cash$750.74M
Total Debt$1.04B
Free Cash Flow$208.26M

Source: Nexqual, July 25, 2026 at 01:44 UTC.

Financial Health Score (TDOC)

Nexqual rates Teladoc Health, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:44 UTC.

GrowthWeak — Revenue -2% YoY (annual), declining
ProfitabilitySolid — Gross margin 69%, operating -8%
Balance SheetMixed — $751M cash vs $1.04B debt
Cash FlowSolid — FCF $208M, 8% margin
EfficiencyCritical — ROE -12%, ROA -3.1%

Ownership (TDOC)

Insider Ownership+0.69%
Institutional Ownership+83.69%
Shares Outstanding180.51M
Float179.34M
Short % of Float+15.26%

Source: Nexqual, July 25, 2026 at 01:44 UTC.

Leadership (TDOC)

Teladoc Health, Inc. is led by Charles Divita III (age 55), CEO, Interim Principal Financial Officer & Director, per Nexqual as of July 25, 2026 at 01:44 UTC.

CEO, Interim Principal Financial Officer & DirectorCharles Divita III (age 55)
President of InternationalCarlos Nueno (age 51)
President of U.S. Group HealthKelly M. Bliss (age 50)
Chief Technology OfficerDave Ross
Vice President of Investor RelationsMichael Minchak

Major Backers & Investors (TDOC)

Notable institutional backers of Teladoc Health, Inc. include Renaissance Technologies, Point72 Asset Management, L.P., Voss Capital, LP, according to Nexqual as of July 25, 2026 at 01:44 UTC.

Active Investors

InvestorStake
Renaissance Technologies4.48%
Point72 Asset Management, L.P.4.28%
Voss Capital, LP2.33%
American Century ETF Trust-Avantis U.S. Small Cap Value ETF2.09%

Index Funds (Passive)

FundStake
Vanguard Group19.61%
BlackRock10.45%
Dimensional Fund Advisors3.49%
Allianz Asset Management GmbH2.65%
State Street2.42%
Geode Capital2.32%

Source: Nexqual, July 25, 2026 at 01:44 UTC.

From Teladoc Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
DOCUDocuSign, Inc.USD 50.44▲ 5.32%
ZMZoom Communications, Inc.USD 87.99▲ 2.54%
XYZBlock, Inc.USD 77.15▼ 0.4%
ROKURoku, Inc.USD 141.97▼ 0.78%
FSLYFastly, Inc.USD 20.24▼ 1.08%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:44 UTC. This page is informational and not investment advice.